Research and development expenses increased to $1,300,000 in the fiscal Q3 of 2024 compared to $1,200,000 in the fiscal Q3 of 2023, primarily due to higher staff related expenses, including severance expenses, stock based compensation and general research and development costs. Adjusted EBITDA loss was $1,400,000 in the fiscal Q3 of 2024 as compared to a loss of $700,000 in the fiscal Q3 of 2023, primarily attributable to the impact of lower revenue. Net loss for the fiscal Q3 of 2024 was $2,600,000 compared to a loss of $1,400,000 in the fiscal Q3 of 2023, primarily attributable to decreased gross profit and increases in operating expenses and interest expense to support our planned growth. Cash was $1,300,000 on March 31, 2024 as compared to $2,400,000 at June 30, 2023 based on timing of utilizing our credit line. Net cash used in operating activities decreased by $900,000 to 4,300,000 dollars in the 9 months ended March 31, 2024 compared to $5,200,000 in the 9 months ended March 31, 2023.